Investor News / RNS

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announces it has entered into a partnership with Tabula Rasa HealthCare® (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety. Through this initiative, Physiomics’ personalised docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx®. Both parties...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that its existing client, Merck KGaA (“Merck”), has today committed to an initial tranche of projects for 2021 with an aggregate value of £270,000. These projects are expected to be completed during the first six to eight months of...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that its National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme funded observational clinical study (designated “PARTNER”), has this week received both ethics committee and Health Research Authority (HRA) approval and it is now expected that the...

Read More

Physiomics plc (“Physiomics” “the Company”) Result of AGM Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting, held earlier today at the Company’s offices in Oxford, were duly passed.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Strand Hanson Ltd...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2020, together with its Notice of Annual General Meeting (“AGM”). As announced on 30 September 2020, the Company’s AGM will be...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded further contracts of undisclosed value for projects with existing clients Bicycle Therapeutics plc (“Bicycle”) and Merck KGaA (“Merck”). The project with Bicycle is the eighth signed with this high-profile UK biotech company, spanning four different...

Read More

Physiomics plc (“Physiomics” or “the Company”)  Presentation and Q&A on Company’s Final Results for the year ended 30 June 2020 Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a presentation regarding its final results for the year ended 30 June 2020, using the Investor Meet Company platform.  The slide deck used in...

Read More

Highlights  Financial Highlights Total income (revenue and grant income) increased 7% to £841,649 (2019: £783,101), the highest in the Company’s history The operating loss decreased 33% to £134,385 (2019: £201,219) The loss after taxation decreased 38% to £64,424 (2019: £104,040) Placing and subscription in May 2020 raised £828,750 (gross) through the issue of 23,678,571 new ordinary shares at an issue price of 3.5 pence per share ...

Read More

The Company is pleased to announce that it will release its results for the year ended 30 June 2020 at 7.00 a.m. on Wednesday 30 September 2020. In addition, management is pleased to confirm that they will provide a live presentation relating to the Company’s results via the Investor Meet Company (“IMC”) platform on Monday 5 October 2020, at 11.00 a.m. The online presentation is open...

Read More
})(jQuery)